


Amendments to the Claims

Listing of Claims:


Claim 1 (original): A combination for simultaneous, separate or sequential use which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine of formula I



(I)

or a pharmaceutically acceptable salt thereof and (b) at least one histone deacetylase inhibitor in free form or in a pharmaceutically acceptable salt form thereof and optionally at least one pharmaceutically acceptable carrier.


Claim 2 (original): A combination according to claim 1 wherein (b) is selected from the group consisting of sodium butyrate, MS-275, SAHA, aphacidin, depsipeptide, FK 228, trichostatin A, Compound of formula II or a pharmaceutically acceptable salt



thereof

(II)

and Compound of formula III or a pharmaceutically acceptable salt thereof,



(III),

and optionally at least one pharmaceutically acceptable carrier.

Claim 3 (original): The combination according to claim 2 wherein (b) is selected from the group consisting of sodium butyrate, SAHA, Compound of formula II and Compound of formula III.

Claim 4 (currently amended): Use of a combination according to ~~any one of claims 1 to 3~~claim 1 in the treatment of a leukemia.

Claim 5 (currently amended): Use of a combination according to ~~any one of claims 1 to 3~~claim 1 for the preparation of a medicament in the treatment of a leukemia.

Claim 6 (currently amended): Use of a combination according to ~~any one of claim 4 or 5~~claim 4 wherein the leukemia is a Compound I-resistant leukemia.

Claim 7 (currently amended): A method of treating a warm-blooded animal having a leukemia comprising administering to the animal a combination according to ~~any one of claims 1 to 3~~claim 1 in a quantity which is jointly therapeutically effective against said leukemia and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.

Claim 8 (currently amended): A pharmaceutical composition comprising a quantity which is jointly therapeutically effective against a leukemia of a pharmaceutical combination according to ~~claim 1 to 3~~claim 1 and at least one pharmaceutically acceptable carrier.

Claim 9 (currently amended): A commercial package comprising a combination according to ~~any one of claims 1 to 3~~ claim 1 together with instructions for simultaneous, separate or sequential use thereof in the treatment of a leukemia.

Claim 10 (canceled)